Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.

BGNE

BeiGene (BGNE)

BeiGene Ltd
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:BGNE
FechaHoraFuenteTítuloSímboloCompañía
15/06/202411:05Business WireBeiGene présentera à l’EHA2024 de nouvelles données sur l’étude SEQUOIA évaluant la bithérapie BRUKINSA® plus vénétoclax dans le traitement de première intention de patients atteints de LLC/PLL à haut risqueNASDAQ:BGNEBeiGene Ltd
15/06/202408:42Business WireEHA2024: BeiGene präsentiert neue Daten der SEQUOIA-Studie zu BRUKINSA® plus Venetoclax für die Erstlinienbehandlung von Hochrisiko-CLL/SLLNASDAQ:BGNEBeiGene Ltd
14/06/202405:00Business WireBeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024NASDAQ:BGNEBeiGene Ltd
13/06/202418:41Business WireBeiGene and NewBridge Pharmaceuticals FZ LLC Mutually Agree to Conclude BRUKINSA® (Zanubrutinib) Partnership in the Middle East and Africa (MENA) RegionNASDAQ:BGNEBeiGene Ltd
07/06/202416:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BGNEBeiGene Ltd
05/06/202416:23Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:BGNEBeiGene Ltd
05/06/202415:35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BGNEBeiGene Ltd
04/06/202405:01Business WireBeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:BGNEBeiGene Ltd
28/05/202407:00GlobeNewswire Inc.BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human StudyNASDAQ:BGNEBeiGene Ltd
24/05/202405:00Business WireBRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLLNASDAQ:BGNEBeiGene Ltd
15/05/202417:10Business WireEHA2024: BeiGene präsentiert neues Hämatologie-Portfolio und Pipeline-DatenNASDAQ:BGNEBeiGene Ltd
15/05/202416:50Business WireBeiGene présente de nouvelles données de portefeuille et de pipeline d'hématologie à l'EHA2024NASDAQ:BGNEBeiGene Ltd
14/05/202415:01Business WireBeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024NASDAQ:BGNEBeiGene Ltd
09/05/202414:03Business WireBeiGene meldet Finanzergebnisse für das erste Quartal 2024 und aktuelle GeschäftsentwicklungenNASDAQ:BGNEBeiGene Ltd
09/05/202408:38Business Wireベイジーン、2024年第1四半期決算および事業に関する最新情報を発表NASDAQ:BGNEBeiGene Ltd
08/05/202420:02Business WireBeiGene公布2024年第一季財務業績和最新業務情況NASDAQ:BGNEBeiGene Ltd
08/05/202418:03Business WireBeiGene présente ses résultats financiers du premier trimestre 2024 et ses dernières nouvelles commercialesNASDAQ:BGNEBeiGene Ltd
08/05/202405:00Business WireBeiGene Reports First Quarter 2024 Financial Results and Business UpdatesNASDAQ:BGNEBeiGene Ltd
26/04/202409:34Business WireBeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability ReportNASDAQ:BGNEBeiGene Ltd
25/04/202406:11Business WireGlobaler Onkologie-Innovator BeiGene präsentiert auf der ASCO-Jahrestagung 2024 neue Daten aus dem gesamten Portfolio für Hämatologie und solide TumoreNASDAQ:BGNEBeiGene Ltd
25/04/202406:10Business WireBeiGene, innovateur mondial en oncologie, présente de nouvelles données sur l’ensemble de son portefeuille en hématologie et en tumeurs solides lors de la réunion annuelle de l’ASCO 2024NASDAQ:BGNEBeiGene Ltd
24/04/202415:01Business WireGlobal Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual MeetingNASDAQ:BGNEBeiGene Ltd
23/04/202418:31Business WireBeiGene erhält von der EU-Kommission die Zulassung für Tislelizumab zur Behandlung von nicht kleinzelligem LungenkrebsNASDAQ:BGNEBeiGene Ltd
23/04/202418:31Business WireBeiGene reçoit l’approbation de la Commission européenne pour le tislelizumab dans le traitement du cancer du poumon non à petites cellulesNASDAQ:BGNEBeiGene Ltd
23/04/202405:00Business WireBeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung CancerNASDAQ:BGNEBeiGene Ltd
16/03/202410:18Business WireBeiGene、化学療法後の進行性または転移性食道扁平上皮癌の治療のためのTEVIMBRA®のFDA承認取得NASDAQ:BGNEBeiGene Ltd
15/03/202416:13Business Wire百濟神州喜獲FDA批准,TEVIMBRA®將用於晚期或轉移性食管鱗狀細胞癌在化療後的治療NASDAQ:BGNEBeiGene Ltd
15/03/202415:02Business WireBeiGene reçoit l'approbation de la FDA pour TEVIMBRA® dans le traitement du carcinome épidermoïde de l’œsophage avancé ou métastatique après une chimiothérapieNASDAQ:BGNEBeiGene Ltd
15/03/202401:06Business WireBeiGene erhält FDA-Zulassung für TEVIMBRA ® zur Behandlung des fortgeschrittenen oder metastasierten Plattenepithelkarzinoms der Speiseröhre nach vorheriger ChemotherapieNASDAQ:BGNEBeiGene Ltd
14/03/202415:28Business WireBeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior ChemotherapyNASDAQ:BGNEBeiGene Ltd
 Showing the most relevant articles for your search:NASDAQ:BGNE

Su Consulta Reciente

Delayed Upgrade Clock